Published in J Biol Chem on March 11, 2010
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell (2014) 3.68
p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49
Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27
Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem (2010) 1.16
The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci (2013) 1.07
More targets, more pathways and more clues for mutant p53. Oncogenesis (2013) 1.00
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res (2016) 0.94
Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity. Cell Cycle (2012) 0.91
MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3. BMC Cancer (2013) 0.89
Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications. Cell Death Dis (2015) 0.87
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53. Obstet Gynecol Int (2013) 0.86
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. PLoS One (2015) 0.85
Prognostic Impact of del(17p) and del(22q) as assessed by interphase FISH in sporadic colorectal carcinomas. PLoS One (2012) 0.84
Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells. PLoS One (2013) 0.83
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecol Oncol (2012) 0.83
Restin suppressed epithelial-mesenchymal transition and tumor metastasis in breast cancer cells through upregulating mir-200a/b expression via association with p73. Mol Cancer (2015) 0.82
YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep (2015) 0.81
Whole-genome cartography of p53 response elements ranked on transactivation potential. BMC Genomics (2015) 0.80
Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther (2014) 0.80
Mutant p53-Notch1 Signaling Axis Is Involved in Curcumin-Induced Apoptosis of Breast Cancer Cells. Korean J Physiol Pharmacol (2013) 0.79
Zn(II)-curc targets p53 in thyroid cancer cells. Int J Oncol (2015) 0.78
Weight loss reduces basal-like breast cancer through kinome reprogramming. Cancer Cell Int (2016) 0.75
MKK3 as oncotarget. Aging (Albany NY) (2016) 0.75
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
The p53 pathway: positive and negative feedback loops. Oncogene (2005) 9.75
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science (1995) 7.87
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med (1996) 7.32
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol (2003) 6.21
p53 and human cancer: the first ten thousand mutations. Adv Cancer Res (2000) 4.71
Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res (2001) 4.50
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 4.10
A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res (1998) 3.20
Rescuing the function of mutant p53. Nat Rev Cancer (2001) 2.95
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene (2006) 2.33
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene (2006) 2.01
Transcription regulation by mutant p53. Oncogene (2007) 1.78
Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem (2001) 1.67
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem (2000) 1.64
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res (2004) 1.59
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene (1995) 1.52
Modulation of gene expression by tumor-derived p53 mutants. Cancer Res (2004) 1.52
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. Nucleic Acids Res (1987) 1.49
Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations. Cancer Res (2008) 1.41
The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol (2009) 1.39
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
RNAi Codex: a portal/database for short-hairpin RNA (shRNA) gene-silencing constructs. Nucleic Acids Res (2006) 1.35
MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther (2007) 1.33
Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J (2001) 1.32
Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res (2006) 1.32
Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene (2003) 1.28
Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem (2009) 1.27
Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem (2004) 1.27
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene (2006) 1.23
NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PLoS One (2008) 1.05
Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences. Nucleic Acids Res (2009) 0.92
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 4.10
The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell (2005) 2.45
Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol (2005) 2.13
MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell (2007) 2.10
Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem (2002) 1.91
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ Res (2008) 1.75
YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem (2003) 1.51
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest (2009) 1.51
DNA damage induced by temozolomide signals to both ATM and ATR: role of the mismatch repair system. Mol Pharmacol (2004) 1.40
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle (2008) 1.36
Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer. Mol Cancer Res (2006) 1.33
Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 1.29
Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res (2004) 1.25
The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J (2009) 1.23
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J (2009) 1.23
HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene (2005) 1.20
Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer (2009) 1.19
Requirement for down-regulation of the CCAAT-binding activity of the NF-Y transcription factor during skeletal muscle differentiation. Mol Biol Cell (2003) 1.19
Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin Cancer Res (2008) 1.18
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther (2009) 1.17
Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res (2008) 1.17
Expression of Slug is regulated by c-Myb and is required for invasion and bone marrow homing of cancer cells of different origin. J Biol Chem (2010) 1.16
HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res (2009) 1.15
Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. J Clin Invest (2002) 1.14
Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res (2012) 1.14
Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck (2007) 1.13
HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene (2004) 1.12
Evidences that leptin up-regulates E-cadherin expression in breast cancer: effects on tumor growth and progression. Cancer Res (2007) 1.11
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta (2008) 1.11
MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem (2003) 1.10
Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol (2006) 1.09
Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. PLoS One (2008) 1.08
Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha. PLoS One (2009) 1.08
HIPK2 modulates p53 activity towards pro-apoptotic transcription. Mol Cancer (2009) 1.08
Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation. Cancer Res (2010) 1.07
Effects of assessing the productivity of faculty in academic medical centres: a systematic review. CMAJ (2012) 1.06
Posttranslational regulation of NF-YA modulates NF-Y transcriptional activity. Mol Biol Cell (2008) 1.06
AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol (2008) 1.06
NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PLoS One (2008) 1.05
The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs. Cell Cycle (2008) 1.05
Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res (2008) 1.05
MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. Oncogene (2002) 1.04
The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function. Cancer Res (2007) 1.04
Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis. Free Radic Biol Med (2010) 1.03
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res (2005) 1.03
HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations. FEBS Lett (2005) 1.02
Telomerase mediates vascular endothelial growth factor-dependent responsiveness in a rat model of hind limb ischemia. J Biol Chem (2005) 1.01
Endogenous NGF regulates CGRP expression in human monocytes, and affects HLA-DR and CD86 expression and IL-10 production. Blood (2005) 1.00
Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J (2009) 1.00
Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res (2007) 0.96
CD34-positive cells in human umbilical cord blood express nerve growth factor and its specific receptor TrkA. J Neuroimmunol (2003) 0.95
Hypoxia-inducible factor 1-α induces miR-210 in normoxic differentiating myoblasts. J Biol Chem (2012) 0.95
Purification and characterization of adipose-derived stem cells from patients with lipoaspirate transplant. Cell Transplant (2010) 0.94
Loss of beta4 integrin subunit reduces the tumorigenicity of MCF7 mammary cells and causes apoptosis upon hormone deprivation. Clin Cancer Res (2006) 0.94
Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J Mol Med (Berl) (2008) 0.92
A nitric oxide-dependent cross-talk between class I and III histone deacetylases accelerates skin repair. J Biol Chem (2013) 0.91
Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res (2006) 0.91
Che-1 promotes tumor cell survival by sustaining mutant p53 transcription and inhibiting DNA damage response activation. Cancer Cell (2010) 0.90
deltaEF1 repressor controls selectively p53 family members during differentiation. Oncogene (2005) 0.90
Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression. Cancer Res (2009) 0.89
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. Clin Cancer Res (2006) 0.88
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer (2010) 0.88
Human papillomavirus-16 E7 interacts with Siva-1 and modulates apoptosis in HaCaT human immortalized keratinocytes. J Cell Physiol (2007) 0.88
Abscopal effect of radiation therapy: Interplay between radiation dose and p53 status. Int J Radiat Biol (2014) 0.87
Tp53-gene transfer induces hypersensitivity to low doses of X-rays in glioblastoma cells: a strategy to convert a radio-resistant phenotype into a radiosensitive one. Cancer Lett (2006) 0.87
Maternal thyroid hormones are transcriptionally active during embryo-foetal development: results from a novel transgenic mouse model. J Cell Mol Med (2010) 0.87
Molecular imaging of nuclear factor-Y transcriptional activity maps proliferation sites in live animals. Mol Biol Cell (2012) 0.86
Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors. PLoS One (2012) 0.85
PKC theta ablation improves healing in a mouse model of muscular dystrophy. PLoS One (2012) 0.85
HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA. Biochem Biophys Res Commun (2007) 0.84
Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer (2008) 0.84
Long telomeric C-rich 5'-tails in human replicating cells. J Biol Chem (2002) 0.84
In vivo and in vitro evidence that PPARγ ligands are antagonists of leptin signaling in breast cancer. Am J Pathol (2011) 0.83
Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene (2004) 0.83
Analysis of biodistribution and engraftment into the liver of genetically modified mesenchymal stromal cells derived from adipose tissue. Cell Transplant (2012) 0.83
Pincer and diamine Ru and Os diphosphane complexes as efficient catalysts for the dehydrogenation of alcohols to ketones. Chemistry (2011) 0.83
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound. Pharmacol Res (2009) 0.82
Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. J Transl Med (2008) 0.81
Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. J Cell Physiol (2009) 0.80
Cytogenetic analysis of human cells reveals specific patterns of DNA damage in replicative and oncogene-induced senescence. Aging Cell (2012) 0.80
Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. Int J Cancer (2012) 0.80
Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells. J Thorac Oncol (2011) 0.79
Combining optimization and machine learning techniques for genome-wide prediction of human cell cycle-regulated genes. Bioinformatics (2013) 0.78
Kinetic heterogeneity of an experimental tumour revealed by BrdUrd incorporation and mathematical modelling. Bull Math Biol (2002) 0.78
Phenotypic and genotypic characteristics of new euploid-diploid lymphoblastoid B cell lines EBV+, normal human bone marrow derived, spontaneously overgrown in vitro. J Virol Methods (2005) 0.78